z-logo
open-access-imgOpen Access
Comparison of weekly and daily recall of pain as an endpoint in a randomized phase 3 trial of cabozantinib for metastatic castration-resistant prostate cancer
Author(s) -
E.M. Schaffer,
E.M. Basch,
G.M. Schwab,
Antonia V. Bennett
Publication year - 2021
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/74s7-m110
Subject(s) - cabozantinib , prostate cancer , clinical endpoint , medicine , randomized controlled trial , oncology , cancer

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom